Recently, Johnson & Johnson announced that it has completed the acquisition of Swiss biotechnology company Actelion for US$30 billion. US healthcare giant, all-cash transaction at $ 280 per share to complete the acquisition. The company said the acquisition is expected to add $1.3 billion in sales to Johnson & Johnson in 2017. In January of this year, Johnson & Johnson officially agreed to announce the acquisition of Actelion for $30 billion. Actelion's deal helped Johnson & Johnson quickly make up for lost sales. Some commentators said that through this transaction, Johnson & Johnson will once again become a leader in new disease areas in areas such as autoimmune diseases, heart disease and cancer. Alex Gorsky, chairman and CEO of Johnson & Johnson, said: "We are very pleased to be able to complete this compelling deal and look forward to Johnson & Johnson bringing value to patients with pulmonary hypertension and other serious diseases worldwide. Investing Actelion Expanded our product portfolio to our strong pharmaceutical business." "Through this transaction, Johnson & Johnson will set up a sixth therapeutic area, which will be our growth engine, because our team is based on the Actelion market leader." Joaquin Duato, vice president and global pharmaceutical director of Johnson & Johnson, said: "Actelion's PAH franchise, including differentiated innovative drugs Opsumit, Uptravi and Tracleer expands Johnson & Johnson's business and gives the company a leading position in the field of translational medicine innovation for major diseases and unmet medical needs." Foot and leg massager Foot and leg massager Shenzhen Jie Zhong Lian Investment Co., Ltd. , https://www.meizons.com